Paper Details

  1. Home
  2. Paper Details

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

Author: ChaparroM, GisbertJ P, MarínA C, McNichollA G

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

The efficacy of a second anti-TNF in CD patients largely depends on the cause for switching. The remission rate is higher when the reason to withdraw the first anti-TNF is intolerance (61%), compared with secondary (45%) or primary failure (30%).
Paper Details　
Original Abstract of the Article :
BACKGROUND: One-third of patients with Crohn's disease (CD) or ulcerative colitis (UC) receiving anti-TNFs do not respond to treatment, and a relevant proportion experience loss of response or intolerance. AIM: To investigate the efficacy and safety of a second anti-TNF agent after primary/secondar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/apt.13083

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Inflammatory Bowel Disease Treatment

The treatment of [Inflammatory Bowel Disease (IBD)] is often a journey of trial and error, with many patients seeking effective alternatives when initial therapies fail. This study investigates the effectiveness of switching to a second [Anti-TNF Agent] in patients who do not respond to the first. The researchers analyzed data from studies evaluating the use of [Infliximab (IFX)], [Adalimumab (ADA)], and [Certolizumab-pegol (CZP)] as second-line therapies. Their findings suggest that switching to a second anti-TNF agent, especially in cases of intolerance to the first, can be a viable option for many patients. The study highlights the importance of individualizing treatment strategies based on the specific needs of each patient.

Second-Line Anti-TNF Therapy: A Promising Option for IBD Patients

This research offers valuable insights into the efficacy of switching to a second anti-TNF agent in IBD patients. The study found that the remission rates were higher when the switch was due to intolerance to the first anti-TNF compared to primary or secondary failure. This highlights the importance of considering the underlying reasons for treatment failure when making treatment decisions.

Finding the Right Path to IBD Treatment: A Journey of Personalized Medicine

This study emphasizes the need for personalized treatment approaches in IBD. It underscores the importance of carefully assessing each patient's individual response to therapy and adapting the treatment regimen accordingly. This research provides valuable data to support informed decision-making in this complex area of medicine.

Dr.Camel's Conclusion

The world of IBD treatment is like a shifting desert landscape, where the path to recovery can be unpredictable. This study provides valuable guidance for navigating these sands, highlighting the effectiveness of switching to a second anti-TNF agent in certain circumstances. It's a reminder that finding the right treatment is a journey of discovery, where each patient's needs must be carefully considered.

Date :
  1. Date Completed 2015-08-13
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

25652884

DOI: Digital Object Identifier

10.1111/apt.13083

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.